StockData
Veracyte, Inc. logo

Veracyte, Inc. (VCYT) stock

VCYTNasdaqServices-Medical LaboratoriesFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 5, 2026Score 16/3034% below fair value
$24.23+0.22 (+0.92%)

Close on Nov 17, 2026Market cap $1.95BP/E 17.3Yield –

Veracyte gross margin

Gross margin is gross profit as a percentage of revenue.

Veracyte's gross margin for the twelve months ending Jun 30, 2026 was 71.7%. For fiscal 2025 it was 70.1%, against 66.9% the year before. The highest annual figure on record is 70.1% in fiscal 2025.

Annual gross margin

PeriodPeriod endValueChange (pts)
FY2025Dec 31, 202570.1%+3.2
FY2024Dec 31, 202466.9%+3.3
FY2023Dec 31, 202363.6%+4.4
FY2022Dec 31, 202259.2%−10.8
FY2019Dec 31, 201970.0%+6.0
FY2018Dec 31, 201864.0%+3.2
FY2017Dec 31, 201760.8%−0.1
FY2016Dec 31, 201660.9%+4.3
FY2015Dec 31, 201556.6%+0.1
FY2014Dec 31, 201456.5%+14.1
FY2013Dec 31, 201342.4%+7.6
FY2012Dec 31, 201234.8%+45.4
FY2011Dec 31, 2011-10.6%–

Quarterly gross margin

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange (pts)
Q2 FY2026Jun 30, 202672.2%+3.2
Q1 FY2026Mar 31, 202672.7%+3.3
Q4 FY2025Dec 31, 202572.5%+6.1
Q3 FY2025Sep 30, 202569.2%+1.0
Q2 FY2025Jun 30, 202569.0%+0.9
Q1 FY2025Mar 31, 202569.5%+5.0
Q4 FY2024Dec 31, 202466.4%+0.4
Q3 FY2024Sep 30, 202468.2%+4.2
Q2 FY2024Jun 30, 202468.1%+6.3
Q1 FY2024Mar 31, 202464.5%−3.0
Q4 FY2023Dec 31, 202366.0%−4.6
Q3 FY2023Sep 30, 202364.0%−6.9
Q2 FY2023Jun 30, 202361.8%−9.4
Q4 FY2019Dec 31, 201967.5%+1.3
Q3 FY2019Sep 30, 201970.6%+5.8
Q2 FY2019Jun 30, 201970.9%+7.1
Q1 FY2019Mar 31, 201971.2%+10.4
Q4 FY2018Dec 31, 201866.2%+5.8
Q3 FY2018Sep 30, 201864.8%+5.7
Q2 FY2018Jun 30, 201863.8%+1.6
Q1 FY2018Mar 31, 201860.7%−0.9
Q4 FY2017Dec 31, 201760.4%−4.0
Q3 FY2017Sep 30, 201759.1%−6.7
Q2 FY2017Jun 30, 201762.2%–
Q1 FY2017Mar 31, 201761.7%–
Q4 FY2016Dec 31, 201664.3%–
Q3 FY2016Sep 30, 201665.8%–

More Veracyte figures

See a number that looks wrong?